GlassScriptPhysician profile
Fang L Lin
NPI 1811968464
$3,381.41
in general payments reported to CMS, 2019-2025
19 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $38.68 · 2021: $775 · 2022: $1,067 · 2023: $119 · 2024: $101 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $466.22 | 2019-2022 | |
| Csl Behring | $372.42 | 2019-2025 | Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $369.08 | 2019-2023 | |
| Grifols USA, LLC | $358.25 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $327.00 | 2021-2022 | |
| Genzyme Corporation | $246.37 | 2021-2022 | |
| Shire North American Group INC | $225.45 | 2019 | |
| Pfizer INC. | $219.64 | 2019-2022 | |
| Optinose US, INC. | $134.66 | 2019 | |
| Horizon Therapeutics Plc | $114.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $113.61 | 2019 | |
| Genentech USA, INC. | $113.40 | 2019 | |
| Biocryst US Sales Co., LLC | $109.55 | 2021 | |
| Abbvie INC. | $100.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.68 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $23.21 | 2022 | |
| Genentech, INC. | $18.33 | 2022 | |
| Circassia INC. | $17.44 | 2019 | |
| Kaleo, INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.